A5032428632- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Molecular Biology Techniques and Applications
- Quinazolinone synthesis and applications
- Lymphoma Diagnosis and Treatment
- Synthesis and biological activity
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Cancer therapeutics and mechanisms
- Ferroptosis and cancer prognosis
- Cancer-related molecular mechanisms research
- Genomics and Phylogenetic Studies
- PI3K/AKT/mTOR signaling in cancer
- Cancer-related gene regulation
- Epigenetics and DNA Methylation
- DNA Repair Mechanisms
- Gastrointestinal Tumor Research and Treatment
- Neuroendocrine Tumor Research Advances
Genesee Community College
2018-2025
Wenzhou Medical University
2025
First Affiliated Hospital of Wenzhou Medical University
2025
North Sichuan Medical University
2025
Affiliated Hospital of Southwest Medical University
2023-2024
First Hospital of Shijiazhuang
2024
Pennsylvania State University
2021-2024
Affiliated Hospital of Chengde Medical College
2021-2024
BGI Research
2024
University of Macau
2024
Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with T790M-positive non-small cell lung cancer (NSCLC) who have developed resistance earlier-generation drugs. Acquired C797S mutation has been reported mediate in some patients. However, the remaining mechanisms are largely unknown.Experimental Design: We performed profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant patients'...
Abstract Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer management. However, molecular determinants of response to ICIs remain incompletely understood. Experimental Design: We performed genomic profiling 78 patients with non–small cell lung (NSCLC) who underwent anti–PD-(L)1 therapies by both whole-exome and targeted next-generation sequencing (a 422-cancer-gene panel) explore the predictive biomarkers ICI response. Tumor mutation burden (TMB), specific somatic...
For locally advanced rectal cancer (LARC) patients who receive neoadjuvant chemoradiotherapy (nCRT), there are no reliable indicators to accurately predict pathological complete response (pCR) before surgery. with clinical (cCR), a "Watch and Wait" (W&W) approach can be adopted improve quality of life. However, W&W may increase the recurrence risk in judged cCR but have minimal residual disease (MRD). Magnetic resonance imaging (MRI) is major tool evaluate nCRT; however, its ability pCR...
Abstract Manufacturing whole cancer cell vaccines (WCCV) with both biosafety and efficacy is crucial for tumor immunotherapy. Pyroptotic cells, due to their highly immunogenic properties, present a promising avenue the development of WCCV. However, successful WCCV based on pyroptotic cells yet be accomplished. Here, facile strategy that utilized photocatalytic carbon dots (CDs) induce pyroptosis fabricating reported. Photocatalytic CDs are capable generating substantial amounts hydroxyl...
Cancer is a disease of complex genetic alterations, and comprehensive diagnosis beneficial to match each patient appropriate therapy. However, acquisition representative tumor samples invasive sometimes impossible. Circulating DNA (ctDNA) promising tool use as non-invasive biomarker for cancer mutation profiling. Here we implemented targeted next generation sequencing (NGS) with customized gene panel 382 cancer-relevant genes on 605 ctDNA in multiple types. Overall, tumor-specific mutations...
Objective To monitor trastuzumab resistance and determine the underlying mechanisms for limited response rate rapid emergence of HER2+ metastatic gastric cancer (mGC). Design Targeted sequencing 416 clinically relevant genes was performed in 78 paired plasma tissue biopsy samples to plasma-tissue concordance. Then, we longitudinal analyses 97 serial collected from 24 patients who were track during treatment validated identified candidate genes. Results The results targeted sequencing-based...
Background Patients with brain metastases (BMs) have a poor prognosis and limited therapeutic options. Lung cancer is the most common primary malignancy giving rise to BMs; thus, understanding molecular mechanisms behind increased BM risk essential for identifying targets developing effective interventions. Methods Sixty‐one patients who underwent surgical resection of non–small cell lung (NSCLC) BMs were retrospectively studied. Comprehensive genomic profiling NSCLC matched was performed...
Pleural effusion (PE) is commonly observed in advanced lung cancer and was suggested to contain both cell-free tumor DNA cells. Molecular profiling of PE represents a minimally invasive approach detecting driver mutations for clinical decision making, especially when tissues are not available. The objective this study investigate the efficacy precision gene alterations samples address feasibility use. Methods: Sixty-three metastatic patients with (n=30, cohort 1) or without (n=33, 2) matched...
Early detection of primary liver cancer (PLC), including HCC, intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC (cHCC-ICC), is essential for patients' survival. This study aims to develop an accurate affordable method PLC early differentiating ICC from HCC using plasma cell-free DNA (cfDNA) fragmentomic profiles.Whole-genome sequencings (WGS) were performed cfDNA samples 192 patients with (159 26 ICC, 7 cHCC-ICC) 170 noncancer controls (including 53 cirrhosis [LC] or HBV-positive)...
Abstract The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival resected EGFR -mutant stage II–IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable clinical outcomes with tyrosine kinase inhibitors (TKI), raising necessity for further biomarker assessment. In this work, by comprehensive genomic profiling 171 tumor tissues from trial, five predictive biomarkers are identified ( TP53 exon4/5...
TRK fusions are rare but targetable mutations which occur across a wide variety of cancer types. We report the prevalence approximately 0.7% for NTRK-positive colorectal (CRC) by genetically profiling 2519 colonic and rectal tumors. The aberrations APC TP53 frequently co-occurred with NTRK gene fusions, whereas RAS/BRAF oncogenic alterations were almost always mutually exclusive. NTRK-driven patients demonstrated increased TMB (median = 53 mut/MB, 95% CI: 36.8-68.0 mut/MB), high...
Rationale: Cell-free DNA (cfDNA) analysis holds promise for early detection of lung cancer and benefits patients with higher survival. However, the sensitivity previous cfDNA-based studies was still low to suffice clinical use, especially early-stage tumors. Objectives: Establish an accurate affordable approach by integrating cfDNA fragmentomics machine learning models. Methods: This study included 350 participants without 432 cancer. The participants' plasma samples were profiled...
The effect of atovarstatin on digoxin pharmacokinetics was assessed in 24 healthy volunteers two studies. Subjects received 0.25 mg daily for 20 days, administered alone the first 10 days and concomitantly with or 80 atorvastatin last days. Mean steady-state plasma concentrations were unchanged by administration atorvastatin. following slightly higher than alone, resulting 20% 15% Cmax AUC(0-24) values, respectively. Since tmax renal clearance not significantly affected, results are...
EGFR exon 20 insertions ( e20ins) account for up to 10% of mutations in lung cancer; however, tumors with e20ins had poor response rates tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib, and osimertinib, the heterogeneity further complicates clinical studies. Here, we retrospectively screened next‐generation sequencing (NGS) data from 24 468 cancer patients, a total 85 unique variants were identified 547 cases (2.24%), p.A767_V769dup (25.1%) p.S768_D770dup (17.6%)...
Early diagnosis benefits lung cancer patients with higher survival, but most are diagnosed after metastasis. Although cell-free DNA (cfDNA) analysis holds promise, its sensitivity for detecting early-stage is unsatisfying. We leveraged cfDNA fragmentomics to develop a predictive model invasive stage I adenocarcinoma (LUAD).292 LUAD from three medical centers were included together 230 healthy controls whose plasma samples profiled by whole-genome sequencing (WGS). Multiple fragmentomic motif...
Abstract Background Homologous recombination deficiency (HRD) is a molecular biomarker for administrating PARP inhibitor (PARPi) or platinum-based (Pt) chemotherapy. The most well-studied mechanism of causing HRD pathogenic BRCA1/2 mutations, while phenotype also present in patients without alterations, suggesting other unknown factors. Methods targeted next-generation sequencing (GeneseeqPrime® HRD) was used to evaluate the scores 199 (Cohort I). In Cohort II, total 85...